ENFERMEDADES INFECCIOSAS. VIH

Grupo de investigación clínica centrado en patología infecciosa: vih, hepatitis por vhc, e infección osteoarticular. OBJETIVOS: Valorar efectos adversos a largo plazo de los fármacos antirretrovirales de uso actual; Investigación de eficacia-seguridad de nuevas dianas de fármacos anti-VIH y anti-VHC; Investigación de factores pronósticos de respuesta virológica a dichas enfermedades. Determinación de eficacia de antibióticos en espaciadores de cemento como tratamiento de la infección osteoarticular: puesta a punto de modelos farmacocinéticos de antibióticos en diversos materiales protésicos.

Lineas de investigación

Palabras clave

VIH, VHC, Infección Osteoarticular

Miembro
LÓPEZ RUZ, MIGUEL ÁNGEL
LINDE RODRÍGUEZ, ANGEL
HERNÁNDEZ QUERO, JOSÉ
MARTÍNEZ PÉREZ, Mª ÁNGELES
LARA JIMÉNEZ, Mª ÁNGELES
GUIRAO ARRABAL, EMILIO
JAVIER MARTÍNEZ, ROSARIO
FLORIDO LÓPEZ, JOSÉ FERNANDO
LÓPEZ ESPADA, CRISTINA
RUIZ VILLAVERDE, GONZALO
GARCÍA RÓSPIDE, VICENTE
ROJAS VÍLCHEZ, MARÍA JOSÉ
MUÑOZ MEDINA, LEOPOLDO
SANCHEZ CABRERA, VALME
PÉREZ VALLECILLOS, PABLO
TAPIA GÓMEZ, ANTONIO
HIDALGO TENORIO, CARMEN
PARDO MORENO, PEDRO
GARCÍA VALLECILLOS, CORAL
PASQUAU LIAÑO, JUAN

Pérez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Crespo M, Hernández-Quero J, Iribarren JA, Gutiérrez F, Terrón A, Esteban H, Pérez-Molina JA, GESIDA 7011 Study Group members

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.

The Journal of antimicrobial chemotherapy, 2018; 73(9); 2444-2451

FI: 5.217; Q1 / D1

Vicent L, Saldivar HG, Bouza E, Muñoz P, Cuerpo G, de Alarcón A, Vidal B, Cobo M, Goenaga MÁ, Carrasco-Chinchilla F, Montejo M, Gálvez-Acebal J, Hidalgo-Tenorio C, Vinuesa-García D, Martínez-Sellés M, GAMES investigators (Appendix 1)

Prognostic implications of a negative echocardiography in patients with infective endocarditis.

European journal of internal medicine, 2018; 52; 40-48

FI: 3.282; Q1 / D2

Palacios Rosario, Mayorga M, González-Domenech CM, Hidalgo-Tenorio C, Galvez C, Muñoz-Medina L, de la Torre J, Lozano A, Castaño M, Omar M, Santos Jesús

Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: the DORIVIR Study

Journal of the International Association of Providers of AIDS Care (JIAPAC), 2018; ;

FI: 12.242; Q1 / D1

Dominguez-Molina B, Ferrando-Martinez S, Tarancon-Diez L, Hernandez-Quero J, Genebat M, Vidal F, Muñoz-Fernandez MA, Leal M, Koup R, Ruiz-Mateos E

Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers.

Frontiers in immunology, 2018; 9; 2897

FI: 5.511; Q1 / D2

Gutierrez-Fernandez J, Medina V, Hidalgo-Tenorio C, Abad R

Two Cases of Neisseria meningitidis Proctitis in HIV-Positive Men Who Have Sex with Men.

Emerging infectious diseases, 2017; 23(3); 542-543

FI: 7.422; Q1 / D2

Pérez-Parra S, Chueca N, Álvarez M, Pasquau J, Omar M, Collado A, Vinuesa D, Lozano AB, Yebra G, García F

High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach.

PloS one, 2017; 12(10); e0186928

FI: 2.766; Q1 / D3

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S, GeSIDA 7011 Study Group

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).

The Journal of antimicrobial chemotherapy, 2017; 72(1); 246-253

FI: 5.217; Q1 / D2

Schalkwijk S, Colbers A, Konopnicki D, Weizsäcker K, Moltó J, Tenorio CH, Hawkins D, Taylor G, Wood C, van der Ende M, Burger D, PANNA network

The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women.

AIDS (London, England), 2016; 30(8); 1239-44

FI: 5.019; Q1 / D2

Pérez-Parra S, Chueca N, Álvarez M, Pasquau J, Omar M, Collado A, Vinuesa D, Lozano AB, Yebra G, García F

Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain.

PloS one, 2016; 11(12); e0168099

FI: 2.806; Q1 / D3

Lopez-Ruz MA, Navas P, López-Zúñiga MA, Gonzalvo MC, Sampedro A, Pasquau J, Hidalgo-Tenorio C, Javier R, Castilla JA

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

PloS one, 2016; 11(7); e0159305

FI: 2.806; Q1 / D3

Neukam K, Espinosa N, Collado A, Delgado-Fernández M, Jiménez-Aguilar P, Rivero-Juárez A, Hontañón-Antoñana V, Gómez-Berrocal A, Ruiz-Morales J, Merino D, Carrero A, Téllez F, Ríos MJ, Hernández-Quero J, de Lagarde-Sebastián M, Pérez-Camacho I, Vera-Méndez F, Macías J, Pineda JA, hEPAtic Study Group

Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.

PloS one, 2016; 11(5); e0155842

FI: 2.806; Q1 / D3

López-Cortés LF, Castaño MA, López-Ruz MA, Rios-Villegas MJ, Hernández-Quero J, Merino D, Jiménez-Aguilar P, Marquez-Solero M, Terrón-Pernía A, Tellez-Pérez F, Viciana P, Orihuela-Cañadas F, Palacios-Baena Z, Vinuesa-Garcia D, Fajardo-Pico JM, Romero-Palacios A, Ojeda-Burgos G, Pasquau-Liaño J

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

PloS one, 2016; 11(2); e0148924

FI: 2.806; Q1 / D3

Torres-Cornejo A, BenMarzouk-Hidalgo OJ, Viciana P, Sánchez B, López-Ruz MA, López-Cortés LF, Gutiérrez-Valencia A

Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2016; 22(1); 98.e7-98.e10

FI: 5.292; Q1 / D1

Ruiz-Morales J, Ivanova-Georgieva R, Fernández-Hidalgo N, García-Cabrera E, Miró JM, Muñoz P, Almirante B, Plata-Ciézar A, González-Ramallo V, Gálvez-Acebal J, Fariñas MC, Bravo-Ferrer JM, Goenaga-Sánchez MA, Hidalgo-Tenorio C, Goikoetxea-Agirre J, de Alarcón-González A, Spanish Collaboration on Endocarditis Group-Grupo de Apoyo al Manejo de la Endocarditis en España (GAMES), Spanish Network for Research in Infectious Diseases (REIPI)

Left-sided infective endocarditis in patients with liver cirrhosis.

The Journal of infection, 2015; 71(6); 627-41

FI: 4.382; Q1 / D2

Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsäcker K, Haberl AE, Moltó J, Hawkins DA, van der Ende ME, Gingelmaier A, Taylor GP, Ivanovic J, Giaquinto C, Burger DM, Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network, PANNA Network

Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015; 61(5); 809-16

FI: 8.736; Q1 / D1

Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, Pineda JA, Pasquau J, Masiá M, Crespo M, Blanco JR, Moreno S

Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.

Antiviral research, 2015; 120; 79-84

FI: 4.909; Q1 / D1

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Navarro J, Esteban H, Moreno S, GESIDA 7011 Study Group

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

The Lancet. Infectious diseases, 2015; 15(7); 775-84

FI: 21.372; Q1 / D1

Torre-Cisneros J, San-Juan R, Rosso-Fernández CM, Silva JT, Muñoz-Sanz A, Muñoz P, Miguez E, Martín-Dávila P, López-Ruz MA, Vidal E, Cordero E, Montejo M, Blanes M, Fariñas MC, Herrero JI, Rodrigo J, Aguado JM

Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015; 60(11); 1642-9

FI: 8.736; Q1 / D1

Pacheco YM, Jarrin I, Rosado I, Campins AA, Berenguer J, Iribarren JA, Rivero M, Muñoz-Medina L, Bernal-Morell E, Gutiérrez F, Leal M, CoRIS

Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.

Antiviral research, 2015; 117; 69-74

FI: 4.909; Q1 / D1

Shaw E, Miró JM, Puig-Asensio M, Pigrau C, Barcenilla F, Murillas J, Garcia-Pardo G, Espejo E, Padilla B, Garcia-Reyne A, Pasquau J, Rodriguez-Baño J, López-Contreras J, Montero M, de la Calle C, Pintado V, Calbo E, Gasch O, Montejo M, Salavert M, Garcia-Pais MJ, Carratalà J, Pujol M, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), Instituto de Salud Carlos III, Madrid, Spain, GEIH (Hospital Infection Study Group)

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.

BMJ open, 2015; 5(3); e006723

FI: 2.562; Q1 / D3

Arias JL, Unciti-Broceta JD, Maceira J, Del Castillo T, Hernández-Quero J, Magez S, Soriano M, García-Salcedo JA

Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis.

Journal of controlled release : official journal of the Controlled Release Society, 2015; 197; 190-8

FI: 7.441; Q1 / D1

Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, Esquivias J, López-Castro R, Ramírez-Taboada J, de Hierro ML, López-Ruiz MA, Martínez RJ, Llaño JP

The role of polymerase chain reaction of high-risk human papilloma virus in the screening of high-grade squamous intraepithelial lesions in the anal mucosa of human immunodeficiency virus-positive males having sex with males.

PloS one, 2015; 10(4); e0123590

FI: 3.057; Q1 / D2

Gálvez-Acebal J, Almendro-Delia M, Ruiz J, de Alarcón A, Martínez-Marcos FJ, Reguera JM, Ivanova-Georgieva R, Noureddine M, Plata A, Lomas JM, de la Torre-Lima J, Hidalgo-Tenorio C, Luque R, Rodríguez-Baño J, Study Group for Cardiovascular Infections, part of the Andalusian Society of Infectious Diseases

Influence of early surgical treatment on the prognosis of left-sided infective endocarditis: a multicenter cohort study.

Mayo Clinic proceedings, 2014; 89(10); 1397-405

FI: 6.262; Q1 / D1

Macías J, Recio E, Márquez M, García C, Jiménez P, Merino D, Muñoz L, Pasquau J, Ojeda G, Bancalero P, Chueca N, Pineda JA

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

HIV medicine, 2014; 15(7); 417-24

FI: 3.988; Q1 / D3

Vinuesa D, Parra-Ruiz J, Chueca N, Alvarez M, Muñoz-Medina L, Garcia F, Hernandez-Quero J

Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes.

AIDS (London, England), 2014; 28(12); 1835-7

FI: 5.554; Q1 / D1

Parra-Ruiz J, Sanjuán C, Muñoz-Medina L, Vinuesa D, Martínez-Pérez MA, Hernández-Quero J

Letter: accuracy of liver stiffness measurement - a comparison of two different FibroScan devices.

Alimentary pharmacology & therapeutics, 2014; 39(12); 1434-5

FI: 5.727; Q1 / D1

Genebat M, Vera F, Hernández-Quero J, Domingo P, Guardiola JM, Martínez-Madrid O, Martínez L, de la Llana FG, Sánchez-Villegas J, Alvarez H, Mariño A, Lluch JF, Martínez-Pérez MA, Marín J, Ruiz-Mateos E, Leal M

Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects.

Antiviral research, 2014; 104; 59-61

FI: 3.938; Q1 / D2

Podzamczer D, Rozas N, Domingo P, Ocampo A, Van den Eynde E, Deig E, Vergara A, Knobel H, Pasquau J, Antela A, Crespo M, Clotet B, Muñoz J, Fernandez P, Geijo P, de Castro ER, Diz J, Casado A, Torres C

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.

Journal of the International AIDS Society, 2014; 17(4 Suppl 3); 19814

FI: 5.09; Q1 / D2

Pasquau J, López-Cortés L, Mayorga MI, Viciana P, Del Mar Arenas M, Ríos MJ, Hernández-Quero J, Castaño M, Merino MD, Márquez M, Vergara A, Terrón A, Téllez F, Hidalgo-Tenorio C

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.

Journal of the International AIDS Society, 2014; 17(4 Suppl 3); 19813

FI: 5.09; Q1 / D2

Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R

Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.

Journal of the International AIDS Society, 2014; 17(4 Suppl 3); 19520

FI: 5.09; Q1 / D2

Valero IP, Pasquau J, Rubio R, Ribero A, Santos J, Sanz J, Mariño A, Crespo M, Hernandez J, Iribarren JA, Gutierrez F, Terron A, Esteban H, Pérez-Molina JA

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.

Journal of the International AIDS Society, 2014; 17(4 Suppl 3); 19656

FI: 5.09; Q1 / D2

López-Cortés LF, Viciana P, Girón-González JA, Romero-Palacios A, Márquez-Solero M, Martinez-Perez MA, López-Ruz MA, de la Torre-Lima J, Téllez-Pérez F, Delgado-Fernández M, Garcia-Lázaro M, Lozano F, Mohamed-Balghata MO, Sociedad Andaluza de Enfermedades Infecciosas

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.

PloS one, 2014; 9(5); e97262

FI: 3.234; Q1 / D2

Hidalgo-Tenorio C, Rivero-Rodriguez M, Gil-Anguita C, Lopez De Hierro M, Palma P, Ramírez-Taboada J, Esquivias J, López-Ruz MA, Javier-Martínez R, Pasquau-Liaño J

Antiretroviral therapy as a factor protective against anal dysplasia in HIV-infected males who have sex with males.

PloS one, 2014; 9(3); e92376

FI: 3.234; Q1 / D2

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

The New England journal of medicine, 2013; 369(19); 1807-18

FI: 54.42; Q1 / D1

Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S, extended SPRING-2 Study Group

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.

The Lancet. Infectious diseases, 2013; 13(11); 927-35

FI: 19.446; Q1 / D1

López-Cortés LE, Del Toro MD, Gálvez-Acebal J, Bereciartua-Bastarrica E, Fariñas MC, Sanz-Franco M, Natera C, Corzo JE, Lomas JM, Pasquau J, Del Arco A, Martínez MP, Romero A, Muniain MA, de Cueto M, Pascual A, Rodríguez-Baño J, REIPI/SAB group

Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013; 57(9); 1225-33

FI: 9.416; Q1 / D1

García-Cabrera E, Fernández-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, Lomas JM, Gálvez-Acebal J, Hidalgo-Tenorio C, Ruíz-Morales J, Martínez-Marcos FJ, Reguera JM, de la Torre-Lima J, de Alarcón González A, Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases, Spanish Network for Research in Infectious Diseases

Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study.

Circulation, 2013; 127(23); 2272-84

FI: 14.948; Q1 / D1

Álvarez Estévez M, Chueca Porcuna N, Guillot Suay V, Peña Monge A, García García F, Muñoz Medina L, Vinuesa García D, Parra Ruiz J, Hernández-Quero J, García García F

Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter.

Journal of clinical microbiology, 2013; 51(5); 1555-7

FI: 4.232; Q1 / D2

Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A, Ruiz J, Vilacosta I, Montejo M, Vallejo N, López-Medrano F, Plata A, López J, Hidalgo-Tenorio C, Gálvez J, Sáez C, Lomas JM, Falcone M, de la Torre J, Martínez-Lacasa X, Pahissa A

Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013; 56(9); 1261-8

FI: 9.416; Q1 / D1

Masiá M, Padilla S, Álvarez D, López JC, Santos I, Soriano V, Hernández-Quero J, Santos J, Tural C, del Amo J, Gutiérrez F, CoRIS

Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy.

AIDS (London, England), 2013; 27(2); 181-9

FI: 6.557; Q1 / D1

Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J

Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm.

The Journal of antimicrobial chemotherapy, 2012; 67(11); 2682-5

FI: 5.338; Q1 / D1

Monge S, Guillot V, Alvarez M, Peña A, Viciana P, García-Bujalance S, Pérez Elias MJ, Iribarren JA, Gutiérrez F, Itziar Casado M, Garcia F, CoRIS

Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012; 18(11); E485-90

FI: 4.578; Q1 / D2

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

The Journal of infectious diseases, 2012; 206(6); 961-8

FI: 5.848; Q1 / D1

Hernando V, Sobrino-Vegas P, Burriel MC, Berenguer J, Navarro G, Santos I, Reparaz J, Martínez MA, Antela A, Gutiérrez F, del Amo J, CoRIS cohort

Differences in the causes of death of HIV-positive patients in a cohort study by data sources and coding algorithms.

AIDS (London, England), 2012; 26(14); 1829-34

FI: 6.407; Q1 / D1

Poveda E, Paredes R, Moreno S, Alcamí J, Córdoba J, Delgado R, Gutiérrez F, Llibre JM, García Deltoro M, Hernández-Quero J, Pulido F, Iribarren JA, García F

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.

AIDS reviews, 2012; 14(3); 208-17

FI: 4.075; Q1 / D2

Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C, SINRES Group

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.

Antimicrobial agents and chemotherapy, 2012; 56(6); 2873-8

FI: 4.565; Q1 / D2

Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, García-Hernández FJ, Castillo-Palma MJ, Sánchez-Román J, Callejas-Rubio JL, Ortego-Centeno N, Egurbide-Arberas MV, Trapiellla-Martínez L, Gallego-Villalobos M, Sáez-Comet L, Velilla-Marco J, Camps-García MT, de Ramón-Garrido E, Esteban Marcos EM, Pallarés-Ferreres L, Hidalgo-Tenorio C, Sabio-Sánchez JM, Gómez-de la Torre R, Salvador-Cervello G, Rios-Blanco JJ, Gil-Aguado A, Vilardell-Tarrés M

Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.

Seminars in arthritis and rheumatism, 2012; 41(6); 789-800

FI: 3.806; Q1 / D3

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S, SENSE Study Team

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.

The Journal of antimicrobial chemotherapy, 2012; 67(3); 685-90

FI: 5.338; Q1 / D1

Molina JM, Lamarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu YP, Zhong L, Margot N, Cheng AK, Chuck SL, Study 145 Team

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

The Lancet. Infectious diseases, 2012; 12(1); 27-35

FI: 19.966; Q1 / D1

Ramírez-Duque N, García-Cabrera E, Ivanova-Georgieva R, Noureddine M, Lomas JM, Hidalgo-Tenorio C, Plata A, Gálvez-Acebal J, Ruíz-Morales J, de la Torre-Lima J, Reguera JM, Martínez-Marcos FJ, de Alarcón A, Grupo para el Estudio de las Infecciones Cardiovasculares de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

Surgical treatment for infective endocarditis in elderly patients.

The Journal of infection, 2011; 63(2); 131-8

FI: 4.126; Q1 / D3

Merchante N, López-Cortés LF, Delgado-Fernández M, Ríos-Villegas MJ, Márquez-Solero M, Merino D, Pasquau J, García-Figueras C, Martínez-Pérez MA, Omar M, Rivero A, Macías J, Mata R, Pineda JA, Grupo Andaluz para el Estudio de las Hepatitis Vıricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.

AIDS patient care and STDs, 2011; 25(7); 395-402

FI: 2.411; Q1 / D2

Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X, BIOGEAS Study Group

Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.

The American journal of medicine, 2011; 124(5); 386-94

FI: 5.43; Q1 / D1

Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Di Lello F, Hernandez-Quero J, Moreno S, Bernal E, Miró JM, Leal M, Gutierrez F, Portilla J, Pineda JA, CoRIS

Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.

AIDS (London, England), 2011; 25(6); 761-6

FI: 6.245; Q1 / D1

Poveda E, Alcamí J, Paredes R, Córdoba J, Gutiérrez F, Llibre JM, Delgado R, Pulido F, Iribarren JA, García Deltoro M, Hernández Quero J, Moreno S, García F

Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists.

AIDS reviews, 2010; 12(3); 135-48

FI: 4.786; Q1 / D2

Arias-Santiago S, Aneiros-Fernández J, Husein-Elahmed H, Girón-Prieto MS, Muñoz-Medina L, Naranjo-Sintes R

Painful red nodule on the right hand.

Cleveland Clinic journal of medicine, 2010; 77(8); 512-5

FI: 3.495; Q1 / D2

Ivanova Georgieva R, García López MV, Ruiz-Morales J, Martínez-Marcos FJ, Lomas JM, Plata A, Noureddine M, Hidalgo-Tenorio C, Reguera JM, De la Torre Lima J, Gálvez Aceval J, Márquez M, de Alarcón A, Andalusian Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases SAEI

Streptococcus agalactiae left-sided infective endocarditis. Analysis of 27 cases from a multicentric cohort.

The Journal of infection, 2010; 61(1); 54-9

FI: 3.805; Q1 / D3

Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P, SWITCHMRK 1 and 2 investigators

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

Lancet (London, England), 2010; 375(9712); 396-407

FI: 33.633; Q1 / D1

Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, Coín MA, Robles-Ortega H, Hidalgo-Tenorio C, Ortego-Centeno N, Callejas-Rubio JL, Jiménez-Alonso J

Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial.

Psychotherapy and psychosomatics, 2010; 79(2); 107-15

FI: 6.0; Q1 / D1

Pérez-Elías MJ, Morellon ML, Ortega E, Hernández-Quero J, Rodríguez-Torres M, Clotet B, Felizarta F, Gutiérrez F, Pineda JA, Nichols G, Lou Y, Wire MB

Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment.

Antimicrobial agents and chemotherapy, 2009; 53(12); 5185-96

FI: 4.802; Q1 / D1

Merchante N, Rivero A, de Los Santos-Gil I, Merino D, Márquez M, López-Ruz MA, Rodríguez-Baño J, Del Valle J, Camacho A, Sanz-Sanz J, Macías J, Pérez-Camacho I, Gómez-Mateos J, Moro A, Pineda JA

Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients.

Gut, 2009; 58(12); 1654-60

FI: 9.357; Q1 / D1

Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009; 49(8); e84-91

FI: 8.195; Q1 / D1

Perez IR, Olry de Labry Lima A, del Castillo LS, Bano JR, Ruz MA, del Arco Jimenez A

No differences in quality of life between men and women undergoing HIV antiretroviral treatment. Impact of demographic, clinical and psychosocial factors.

AIDS care, 2009; 21(8); 943-52

FI: 1.684; Q1 / D2

Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F, OK04 Study Group

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Journal of acquired immune deficiency syndromes (1999), 2009; 51(2); 147-52

FI: 4.207; Q1 / D2

Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J, NODy Study Group

Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.

Journal of acquired immune deficiency syndromes (1999), 2009; 50(4); 390-6

FI: 4.207; Q1 / D2

Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR

Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

Antiviral therapy, 2009; 14(2); 195-201

FI: 4.322; Q1 / D2

Macías J, Orihuela F, Rivero A, Viciana P, Márquez M, Portilla J, Ríos MJ, Muñoz L, Pasquau J, Castaño MA, Abdel-Kader L, Pineda JA, Hepatip Study Group

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

The Journal of antimicrobial chemotherapy, 2009; 63(1); 178-83

FI: 4.352; Q1 / D2

Mira JA, López-Cortés LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, Martín-Rico P, Ríos-Villegas MJ, Hernández-Burruezo JJ, Merino D, López-Ruz MA, Rivero A, Muñoz L, González-Serrano M, Collado A, Macías J, Viciana P, Soriano V, Pineda JA

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

The Journal of antimicrobial chemotherapy, 2008; 62(6); 1365-73

FI: 4.328; Q1 / D2

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008; 47(8); 1083-92

FI: 8.266; Q1 / D1

Palacios R, Terrón A, Hidalgo A, Rivero A, Santos J, SIMVA Group

Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).

The Journal of antimicrobial chemotherapy, 2008; 61(2); 462-3

FI: 4.328; Q1 / D2

Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M, OK04 Study Group

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

AIDS (London, England), 2008; 22(2); F1-9

FI: 5.46; Q1 / D1

Viciana, P.; Deig, E.; Asensi, V.; Pasquau, J.; Martin, T.; Goikoetxea, J.; Flores, J.; Perez, S.; Pedrol, E.

Renal safety profile of TDF in combination with protease inhibitors (PI) in a clinical setting. Results from the PROTECTION cohort

ANTIVIRAL THERAPY, 2007; 12.0;

FI: 4.547; Q1 / D1

Hidalgo-Tenorio, Carmen; Jimenez-Alonso, Juan

Differences between early and late prosthetic valve endocarditis in a series of 169 cases

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007; 130;

FI: 2.338; Q1 / D3

Martin, L; Guillot, V; Alvarez, M; Pena, A; Chueca, N; Hernandez-Quero, J; Garcia, F; Piedrola, G; Maroto, MC

Transmitted Resistance in Newly Diagnosed HIV-Infected Individuals in South Eastern Spain (2005-2007). Detection of Minority Viral Quasispecies

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007; 12.0;

FI: 2.25; Q1 / D3

Título del proyecto: 15_0078 - GILEAD - CARMEN HIDALGO - Curso de formación sobre: Estrategias de tratamiento antirretroviral en diferentes escenarios de pacientes VIH, naïve, simplificación, switch Control de la Toxicidad a largo plazo

Financiador: GILEAD SCIENCES INTERNATIONAL LTD.

Nº Expediente: 15_0078

Ejecución: 2015-2016

IP: CARMEN HIDALGO TENORIO

Título del proyecto: PI 0615-2011 Ensayo clínico en fase IV sobre la efectividad de la vacuna tetravalente del virus papiloma humano (VPH) en la aparición de lesiones displásicas en la mucosa de canal anal de hombres que tienen sexo con hombres (HSH) infectados por el VIH

Financiador: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD

Nº Expediente: PI 0615-2011

Ejecución: 2012-2016

IP: CARMEN HIDALGO TENORIO

Título del proyecto: Epidemiologia y progresion clinica de la infeccion y de las lesiones causadas por el virus del papiloma humano (VPH) en hombres y mujeres infectados por el VIH de la cohorte coris - coris - VPH

Financiador: Instituto de Salud Carlos III

Nº Expediente: 679

Ejecución: 2010-2012

IP: JOSE HERNANDEZ

Título del proyecto: Intervención sobre los profesionales sanitarios para reducir la duración del tratamiento antibiótico en el ámbito Hospitalario

Financiador: Instituto de Salud Carlos III

Nº Expediente: EC08/00298

Ejecución: 2009-2010

IP: JUAN PASQUAU

Título del proyecto: EPIDEMIOLOGÍA DE LA INFECCIÓN Y DE LAS LESIONES CAUSADAS POR EL VIRUS DEL PAPILOMA HUMANO EN LOS HOMBRES Y LAS MUJERES INFECTADOS POR EL VIH DE LA COHORTE CO-RIS

Financiador: Instituto de Salud Carlos III

Nº Expediente: IBS-PI060496

Ejecución: 2007-2009

IP: JOSE HERNANDEZ

Título del ensayo: "Estudio de biomarcadores no intervencionista en pacientes con cáncer de pulmón no microcítico (NSCLC) del tipo histológico adenocarcinoma elegibles para el tratamiento con Vargatef según la ficha técnica autorizada."

Tipo de ensayo: ESTUDIO POSAUTORIZACION COMERCIAL

Financiador: BOEHRINGER INGELHEIM ESPAÑA, S.A.

Nº Expediente: 2016-416-1

Ejecución: 2016-2021

IP: MIRIAM ALONSO GARCIA

Título del ensayo: Estudio Prospectivo No Intervencionista De Pacientes Con Enfermedad De Alzheimer Leve A Moderada Y Sus Cuidadores En Cuatro Países Europeos

Tipo de ensayo: ESTUDIO POSAUTORIZACION COMERCIAL

Financiador: MERCK, SHARP & DOHME CORP.

Nº Expediente: 2016-298-1

Ejecución: 2016-2018

IP: EMILIO FRANCO MACIAS

Título del ensayo: “Estudio de fase 1/2 multicéntrico, abierto, de búsqueda de dosis para evaluar la seguridad, tolerabilidad y eficacia preliminar de nab®-paclitaxel semanal, en pacientes pediátricos con tumores sólidos en recaída o refractarios”.